Colombe Chappey - Genentech | 人才画像

基本信息

浏览量：144

职业迁徙

个人简介

Currently working on clinical trials in Oncology.

研究兴趣

论文共 122 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

TABLE 3 from First-line Avelumab Plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

Duncan Wheatley,Rossana Berardi, Miguel Ángel Climent Durán,Anna Tomiak, Alastair Greystoke, Anthony M. Joshua, Hendrik‐Tobias Arkenau,Lajos Géczi,Javier Garciá Corbacho,Luis Paz‐Ares,Syed A. Hussain, Luboš Petruželka,Angelo Delmonte,Colombe Chappey,Joanna C. Masters,Elisabete Michelon,Danielle A. Murphy, Sandrine Mwewa,Rossano Cesari,Bernard Doger

openalex（2024）

引用0浏览0引用

FIGURE 1 from First-line Avelumab Plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

Duncan Wheatley,Rossana Berardi, Miguel Ángel Climent Durán,Anna Tomiak, Alastair Greystoke, Anthony M. Joshua,Hendrik‐Tobias Arkenau,Lajos Géczi,Javier Garciá Corbacho,Luis Paz‐Ares,Syed A. Hussain, Luboš Petruželka,Angelo Delmonte,Colombe Chappey,Joanna C. Masters,Elisabete Michelon,Danielle A. Murphy, Sandrine Mwewa,Rossano Cesari,Bernard Doger

openalex（2024）

引用0浏览0引用

Abstract PO2-20-03: VERITAC-3: A randomized phase 3 study, with a lead-in, of first-line vepdegestrant + palbociclib vs letrozole + palbociclib in estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer

Seth Wander,Erika Hamilton,Mario Campone,Michael Danso,Sara Hurvitz,Hiroji Iwata,Colombe Chappey,Derek Yang,Julia Perkins Smith,Yuan Liu, Yuanyuan Zhang,Sibyl Anderson,Michelino de Laurentiis

Cancer Research（2024）

引用0浏览0引用

Abstract PO2-20-03: VERITAC-3: A Randomized Phase 3 Study, with a Lead-In, of First-Line Vepdegestrant + Palbociclib Vs Letrozole + Palbociclib in Estrogen Receptor–positive/human Epidermal Growth Factor Receptor 2–negative Advanced Breast Cancer

Seth A. Wander,Erika Hamilton,Mario Campone,Michael Danso,Sara A. Hurvitz,Hiroji Iwata,Colombe Chappey, Dong‐Chu Yang,Julia Perkins Smith,Yuan Liu, Yuanyuan Zhang,Sibyl Anderson,Michelino De Laurentiis

Cancer Researchno. 9_Supplement (2024): PO2-03

引用0浏览0引用

VERITAC-3: A Randomized Phase 3 Study, with a Lead-In, of First-Line Vepdegestrant Plus Palbociclib Vs Letrozole Plus Palbociclib in Estrogen Receptorpositive/human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Seth Wander,Erika Hamilton,Mario Campone,Michael Danso,Sara Hurvitz,Hiroji Iwata,Colombe Chappey,Derek Yang,Julia Perkins Smith,Yuan Liu,Yuanyuan Zhang,Sibyl Anderson,Michelino de Laurentiis

CANCER RESEARCHno. 9 (2024)

引用0浏览0引用

Supplementary Data from A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Nicholas C. Turner,Melinda L. Telli,Hope S. Rugo,Audrey Mailliez,Johannes Ettl,Eva-Maria Grischke,Lida A. Mina,Judith Balmaña,Peter A. Fasching,Sara A. Hurvitz,Andrew M. Wardley,Colombe Chappey,Alison L. Hannah,Mark E. Robson

openalex（2023）

引用0浏览0引用

Global Phase III Studies Evaluating Vepdegestrant in Estrogen Receptor (ER) Plus /human Epidermal Growth Factor Receptor 2 (HER2)- Advanced Breast Cancer: VERITAC-2 and VERITAC-3

H. Iwata,E. P. Hamilton,C. X. Ma,M. De Laurentiis,S. A. Hurvitz,S. A. Wander,M. A. Danso,D. R. Lu,J. Perkins,Y. Liu, L. Tran, S. Anderson,C. Chappey, D. Z. Yang,M. Campone

ANNALS OF ONCOLOGY (2023): S1493-S1493

引用0浏览0引用

73Tip Global Phase III Studies Evaluating Vepdegestrant in Estrogen Receptor (er)+/human Epidermal Growth Factor Receptor 2 (HER2)- Advanced Breast Cancer: VERITAC-2 and VERITAC-3

H. Iwata,E.P. Hamilton,C.X. Ma,M. De Laurentiis,S.A. Hurvitz,S.A. Wander,M.A. Danso,D.R. Lu,J. Perkins,Y. Liu, L. Tran, S. Anderson,C. Chappey, D.Z. Yang,M. Campone

Annals of Oncology (2023): S1493

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn